Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer | Zendy

Yoanna S Pumpalova | Zendy; Margaret M. Kozak | Zendy; Rie von Eyben | Zendy; Pamela L. Kunz | Zendy; George A. Fisher | Zendy; Daniel T. Chang | Zendy; Sigurdís Haraldsdóttir | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer

Author(s) -

Yoanna S Pumpalova,

Margaret M. Kozak,

Rie von Eyben,

Pamela L. Kunz,

George A. Fisher,

Daniel T. Chang,

Sigurdís Haraldsdóttir

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.02.17

Subject(s) - medicine , capecitabine , anal cancer , fluorouracil , exact test , incidence (geometry) , gastroenterology , surgery , colorectal cancer , mann–whitney u test , log rank test , cancer , survival analysis , physics , optics

Capecitabine (Cap) is an established treatment alternative to 5-fluorouracil (5-FU) for chemoradiation in rectal cancer. Few studies have compared the two agents in anal cancer. We compared outcomes and toxicities using Cap versus 5-FU in non-metastatic anal cancer patients at Stanford.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research